PMID- 27788245
OWN - NLM
STAT- MEDLINE
DCOM- 20170606
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 10
DP  - 2016
TI  - Assessment of Interleukin 16 Serum Levels and Skin Expression in Psoriasis 
      Patients in Correlation with Clinical Severity of the Disease.
PG  - e0165577
LID - 10.1371/journal.pone.0165577 [doi]
LID - e0165577
AB  - Interleukin 16 (IL-16) has been described as a significant cytokine involved in 
      the recruitment of CD4+ cells during inflammation; however, its potential role in 
      psoriasis has not been defined. Our aim was to investigate the IL-16 serum levels 
      and IL-16 mRNA skin expression in psoriasis patients in correlation with disease 
      severity and mRNA skin expression for CD4. Moreover, the IL-16 skin localization 
      was assessed and the -295 T/C IL-16 polymorphism was analyzed. For this 
      exploratory, observational, and cross-sectional study, 97 unrelated patients with 
      chronic plaque type psoriasis and 104 healthy controls were enrolled. IL-16 serum 
      levels were significantly increased in patients compared with controls (P = 
      0.000022) and positively correlated with Psoriasis Area and Severity Index (r = 
      0.34, P = 0.0007), Body Surface Area (r = 0.34, P = 0.01) and were significantly 
      higher in individuals with moderate to severe psoriasis (P = 0.0029). There was 
      no significant correlation between IL-16 serum levels and Dermatology Quality of 
      Life Index and no differences in genotype and allele frequencies for -295 T/C 
      IL-16 polymorphism. The expression of IL-16 (mRNA and protein) was elevated in 
      the margin of psoriatic skin while statistically significant increase in IL-16 
      immunoreactivity, but not in mRNA level, was observed within plaques. 
      Furthermore, the IL-16 mRNA levels within psoriatic lesions positively correlated 
      with the levels of CD4 mRNA, but not with Psoriasis Area and Severity Index. In 
      conclusion, our data revealed an association between circulating IL-16 and 
      severity of psoriasis which indicates that this cytokine could serve as a 
      potential marker of disease activity. However, further investigations are 
      required.
FAU - Purzycka-Bohdan, Dorota
AU  - Purzycka-Bohdan D
AD  - Department of Dermatology, Venereology and Allergology, Medical University of 
      Gdansk, Gdansk, Poland.
FAU - Szczerkowska-Dobosz, Aneta
AU  - Szczerkowska-Dobosz A
AD  - Department of Dermatology, Venereology and Allergology, Medical University of 
      Gdansk, Gdansk, Poland.
FAU - Zablotna, Monika
AU  - Zablotna M
AD  - Department of Dermatology, Venereology and Allergology, Medical University of 
      Gdansk, Gdansk, Poland.
FAU - Wierzbicka, Justyna
AU  - Wierzbicka J
AD  - Department of Histology, Medical University of Gdansk, Gdansk, Poland.
FAU - Piotrowska, Anna
AU  - Piotrowska A
AD  - Department of Histology, Medical University of Gdansk, Gdansk, Poland.
FAU - Zmijewski, Michal A
AU  - Zmijewski MA
AD  - Department of Histology, Medical University of Gdansk, Gdansk, Poland.
FAU - Nedoszytko, Boguslaw
AU  - Nedoszytko B
AD  - Department of Dermatology, Venereology and Allergology, Medical University of 
      Gdansk, Gdansk, Poland.
FAU - Nowicki, Roman
AU  - Nowicki R
AD  - Department of Dermatology, Venereology and Allergology, Medical University of 
      Gdansk, Gdansk, Poland.
LA  - eng
PT  - Journal Article
DEP - 20161027
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers)
RN  - 0 (Interleukin-16)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Biomarkers/blood/metabolism
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - Humans
MH  - Interleukin-16/blood/genetics/*metabolism
MH  - Psoriasis/blood/*pathology
MH  - RNA, Messenger/metabolism
MH  - *Severity of Illness Index
MH  - Skin/*metabolism
PMC - PMC5082815
COIS- The authors have declared that no competing interests exist.
EDAT- 2016/10/28 06:00
MHDA- 2017/06/07 06:00
PMCR- 2016/10/27
CRDT- 2016/10/28 06:00
PHST- 2016/09/12 00:00 [received]
PHST- 2016/10/13 00:00 [accepted]
PHST- 2016/10/28 06:00 [pubmed]
PHST- 2017/06/07 06:00 [medline]
PHST- 2016/10/28 06:00 [entrez]
PHST- 2016/10/27 00:00 [pmc-release]
AID - PONE-D-16-36632 [pii]
AID - 10.1371/journal.pone.0165577 [doi]
PST - epublish
SO  - PLoS One. 2016 Oct 27;11(10):e0165577. doi: 10.1371/journal.pone.0165577. 
      eCollection 2016.